Oesophageal CancerNCT07828314
Patient Priorities in the Management of Early Oesophageal Cancer: A Discrete Choice Study
An observational study of Oesophageal Cancer, run by Portsmouth Hospitals NHS Trust at 1 site in United Kingdom.
Trial summary
Understanding patient priorities is important to providing thorough, individualised care in oesophageal cancer. We aim to use questionnaires to explore what is important to patients when considering radical surgery for oesophageal cancer, and to analyse how patients interpret the risk explained to them during the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Oesophageal Cancer
- What is being tested?
- Semi-structured interview and Discrete Choice Experiment
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 118 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 6 Aug 2025to 1 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who are undergoing surveillance or endoscopic treatment for Barret's oesophagus, dysplasia, or oesophageal cancer.
Who may be able to join
- Under care of local MDT for monitoring/surveillance/treatment of Barretts/dysplasia/oesophageal cancer
- able to communicate in English Language
Who cannot join
- Unable or unwilling to give informed consent
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Portsmouth Hospitals University NHS Trust
Portsmouth, Hampshire, PO6 3LY
About this study
Understanding patient priorities is important to providing thorough, individualised care in oesophageal cancer. We aim to use questionnaires to explore what is important to patients when considering radical surgery for oesophageal cancer, and to analyse how patients interpret the risk explained to them during the consent process
- Conditions
- Oesophageal Cancer
- Being tested
- Semi-structured interview, Discrete Choice Experiment
- Medical subject headings
- Esophageal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Semi-structured interviewBehavioural
Interviews will be facilitated by the research team. The sessions will be designed to follow the consolidated criteria for reporting qualitative research (COREQ) (12). The Questionnaire on Distress in Cancer Patients and The Cancer Worry Scale (both validated patient surveys) were also used to help design the script for the interview. The full interview script can be found in a separate document entitled "Patient priorities in Oesophageal Cancer".
Discrete Choice ExperimentBehavioural
Participants will be asked to imagine the following scenario; "You have undergone endoscopic resection for an early oesophageal cancer. All your cancer has been removed, but the histology from your endoscopic resection shows you are at an increased risk of recurrence. This risk could be reduced by undergoing a radical oesophagectomy. The following options are presented to you;"
- Questionnaire will involve choosing between 2 treatments options; Active surveillance or radical surgery.
- 5 attributes will be assigned to each treatment option. Examples of possible attributes; 5-year survival (this pertains to risk of nodal/distant metastases) Risk of mortality from surgery Short-term HRQoL Long-term HRQoL Frequency of invasive tests
- Each attribute will have 3 levels
- It would not be possible to expose patients to all choice sets (>200). Software will be used to design 20 choice sets that will make up the questionnaire.
| Study group | Role | What they receive |
|---|---|---|
| Stage 1 | Semi-structured interviews Receives: Behavioral: Semi-structured interview | |
| Stage 2 | Discrete choice experiment Receives: Behavioral: Discrete Choice Experiment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient priorities
Interview responses and responses from discrete choice experiment.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study start6 Aug 2025
- Primary completion1 Aug 2026
- Study completion1 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oesophageal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 118 participants (actual)
Sponsor and investigators
- Lead sponsor
- Portsmouth Hospitals NHS Trust
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07828314
- Sponsor's protocol ID
- PHU/2025/27
- Status last verified
- Sep 2026
- First submitted
- 14 Sep 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient Priorities in the Management of Early Oesophageal Cancer: A Discrete Choice Study
- ClinicalTrials.gov ID
- NCT07828314
- Acronym / sponsor ID
- PHU/2025/27
- Conditions
- Oesophageal Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 118 participants (actual)
- Lead sponsor
- Portsmouth Hospitals NHS TrustOther government
- Study start
- 6 Aug 2025 (actual)
- Primary completion
- 1 Aug 2026 (actual)
- Study completion
- 1 Aug 2026 (actual)
- First posted
- 18 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Understanding patient priorities is important to providing thorough, individualised care in oesophageal cancer. We aim to use questionnaires to explore what is important to patients when considering radical surgery for oesophageal cancer, and to analyse how patients interpret the risk explained to them during the consent process
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Stage 1 | – | Behavioral: Semi-structured interviewSemi-structured interviews |
| Stage 2 | – | Behavioral: Discrete Choice ExperimentDiscrete choice experiment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who are undergoing surveillance or endoscopic treatment for Barret's oesophagus, dysplasia, or oesophageal cancer.
Key inclusion criteria (2 listed)
- Under care of local MDT for monitoring/surveillance/treatment of Barretts/dysplasia/oesophageal cancer
- able to communicate in English Language
Key exclusion criteria (1 listed)
- Unable or unwilling to give informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Semi-structured interviewInterviews will be facilitated by the research team. The sessions will be designed to follow the consolidated criteria for reporting qualitative research (COREQ) (12). The Questionnaire on Distress in Cancer Patients and The Cancer Worry Scale (both validated patient surveys) were also used to help design the script for the interview. The full interview script can be found in a separate document entitled "Patient priorities in Oesophageal Cancer". | Behavioural | Stage 1 |
| Discrete Choice ExperimentParticipants will be asked to imagine the following scenario; "You have undergone endoscopic resection for an early oesophageal cancer. All your cancer has been removed, but the histology from your endoscopic resection shows you are at an increased risk of recurrence. This risk could be reduced by undergoing a radical oesophagectomy. The following options are presented to you;" - Questionnaire will involve choosing between 2 treatments options; Active surveillance or radical surgery. * 5 attributes will be assigned to each treatment option. Examples of possible attributes; 5-year survival (this pertains to risk of nodal/distant metastases) Risk of mortality from surgery Short-term HRQoL Long-term HRQoL Frequency of invasive tests * Each attribute will have 3 levels * It would not be possible to expose patients to all choice sets (>200). Software will be used to design 20 choice sets that will make up the questionnaire. | Behavioural | Stage 2 |
Primary outcome
Patient priorities
Time frame: 6 months
Interview responses and responses from discrete choice experiment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
Related trials for Oesophageal Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingObservational study
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Oesophageal Cancer, run by Portsmouth Hospitals NHS Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient priorities (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.